PharmaShots Interview: In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets

Shots:Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipelineJay also spoke about the company’s IO targets and other under development immunotherapiesIn addition, the interview provided the corporate and financial updates of the Pyxis OncologySmriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…